ArticleInternational journal of molecular sciences2021
Gran1: A Granulysin-Derived Peptide with Potent Activity against Intracellular
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Characterization of Inflammatory Biomarkers in Palatal Tissue of Patients with Bilateral Cleft Lip and Palate.Life (Basel, Switzerland) · 2026Article
- Review
- HowVaccines · 2026Review
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- CD8+ lymphocytes in immunity against tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Host Immune Response toJournal of inflammation research · 2025Review
- RapTB: a lung-derived hemoglobin fragment with activity againstFrontiers in microbiology · 2025Article
- Lysozyme: an endogenous antimicrobial protein with potent activity against extracellular, but not intracellular Mycobacterium tuberculosis.Medical microbiology and immunology · 2024Article
- Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.Pharmaceutics · 2023Review
- Bioengineered materials with selective antimicrobial toxicity in biomedicine.Military Medical Research · 2023Review
- Vaccine development against tuberculosis before and after Covid-19.Frontiers in immunology · 2023Review
- Antimicrobial peptides´ immune modulation role in intracellular bacterial infection.Frontiers in immunology · 2023Review
- Review
- Immune cell interactions in tuberculosis.Cell · 2022Review
- New Drugs and Novel Cellular Targets against Tuberculosis.International journal of molecular sciences · 2022Article
- A Hot Topic: Cancer Immunotherapy and Natural Killer Cells.International journal of molecular sciences · 2022Review
- Design of a specific peptide against phenolic glycolipid-1 from Mycobacterium leprae and its implications in leprosy bacilli entry.Memorias do Instituto Oswaldo Cruz · 2022Article
- Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Granulysin is an antimicrobial peptide (AMP) expressed by human T-lymphocytes and natural killer cells. Despite a remarkably broad antimicrobial spectrum, its implementation into clinical practice has been hampered by its large size and off-target effects. To circumvent these limitations, we synthesized a 29 amino acid fragment within the putative cytolytic site of Granulysin (termed "Gran1"). We evaluated the antimicrobial activity of Gran1 against the major human pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.